You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BRAF-mutant positive

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in China (Dabrafenib, Trametinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Harbin, Heilongjiang, China
  • +9 more
Jun 13, 2022

First Line Treatment for BRAFV600E Mutant Metastatic Colorectal

Completed
  • BRAF V600E Mutation Positive
  • Metastatic Colorectal Cancer
  • Non Interventional study
  • St. Veit/Glan, Austria
  • +33 more
Jan 20, 2023

Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade

Recruiting
  • Low Grade Glioma (LGG) of Brain With BRAF Aberration
  • +2 more
  • Phoenix, Arizona
  • +12 more
Apr 7, 2022

Melanoma (Skin), Skin Cancer, Skin Melanoma Trial in Tampa (Vemurafenib, Cobimetinib)

Recruiting
  • Melanoma (Skin)
  • +3 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Dec 30, 2022

Colorectal Cancer Metastatic Trial (Tunlametinib plus Vemurafenib, Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy

Not yet recruiting
  • Colorectal Cancer Metastatic
  • Tunlametinib plus Vemurafenib
  • Doublets Chemotherapy ± Bevacizumab or Doublets Chemotherapy ± Cetuximab
  • (no location specified)
Aug 15, 2023

Melanoma Trial in Ottawa, Toronto, Montreal (Vemurafenib, Cobimetinib)

Active, not recruiting
  • Melanoma
  • Ottawa, Ontario, Canada
  • +2 more
Oct 25, 2022

Dabrafenib Plus Trametinib In Rare BRAF V600E Mutation-Positive

Not yet recruiting
  • Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
  • Non-investigational
  • (no location specified)
May 11, 2023

Melanoma Trial in Sydney, Wollstonecraft, Melbourne (Dabrafenib, Trametinib, Pembrolizumab)

Active, not recruiting
  • Melanoma
  • Sydney, New South Wales, Australia
  • +2 more
Apr 4, 2022

Baseline Metastases on Clinical Outcomes Among BRAF Positive

Completed
  • BRAF Positive Metastatic Melanoma
    • East Hanover, New Jersey
      Novartis
    Aug 2, 2023

    Primary Malignant Brain Tumor Trial in China (ABM-1310)

    Not yet recruiting
    • Primary Malignant Brain Tumor
    • Beijing, Beijing, China
    • +3 more
    May 28, 2023

    BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma Trial in Portland (Binimetinib,

    Recruiting
    • BRAF NP_004324.2:p.V600M
    • +6 more
    • Portland, Oregon
      Providence Portland Medical Center
    Aug 17, 2022

    BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer

    Recruiting
    • Metastatic Non-small Cell Lung Cancer
    • BRAF V600 Mutation
      • Lyon, Rhône Alpes, France
        CHU Lyon - Hôpital Cardio-Vasculaire et Pneumologique Louis Prad
      Sep 14, 2022

      Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

      Recruiting
      • Melanoma (Skin)
      • +2 more
        • Evora, Portugal
          Hospital Evora
        May 30, 2022

        Thyroid Carcinoma Trial in New York (Vemurafenib, serial 124I PET/CT, thyrotropin alpha)

        Active, not recruiting
        • Thyroid Carcinoma
        • New York, New York
          Memorial Sloan Kettering Cancer Center
        Feb 28, 2022

        Immunotherapy Among BRAF-Positive Melanoma Patients Treated in

        Completed
        • Metastatic Melanoma
        • East Hanover, New Jersey
          Novartis Investigative Site
        Nov 11, 2022

        BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma Trial in Guangzhou (Encorafenib)

        Completed
        • BRAF V600E Unresectable or Metastatic Melanoma
        • +2 more
        • Guangzhou, Guangdong, China
          Sun Yat-sen University Cancer Center
        Jun 9, 2022

        BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,

        Active, not recruiting
        • BRAF V600E Mutation Present
        • +9 more
        • Boston, Massachusetts
        • +1 more
        Jun 28, 2022

        Advanced BRAF Mutant Melanoma Trial in United States (Trametinib 2 mg daily, hydroxychloroquine (HCQ), dabrafenib 150 mg orally

        Completed
        • Advanced BRAF Mutant Melanoma
        • Trametinib 2 mg daily
        • +2 more
        • Chicago, Illinois
        • +3 more
        Jan 18, 2022

        Advanced Solid Tumor, BRAF V600 Mutation Trial in Nanchang, Jinan, Shanghai (ABM-1310)

        Not yet recruiting
        • Advanced Solid Tumor
        • BRAF V600 Mutation
        • Nanchang, Jiangxi, China
        • +2 more
        Aug 12, 2022

        Targeted Therapies in BRAF Positive Metastatic Melanoma in US

        Active, not recruiting
        • Melanoma
        • New York, New York
          Pfizer Investigational Site
        Feb 18, 2022

        NSCLC, Non-small Cell Carcinoma, Histiocytic Tumor Trial (BDTX-4933)

        Not yet recruiting
        • Non-small Cell Lung Cancer
        • +32 more
        • (no location specified)
        Mar 30, 2023

        Metastatic Melanoma, BRAF Gene Mutation Trial in Lexington (Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg)

        Recruiting
        • Metastatic Melanoma
        • BRAF Gene Mutation
        • Nilotinib 100mg
        • +5 more
        • Lexington, Kentucky
          Markey Cancer Center
        Jul 22, 2022

        Colorectal Cancer, BRAF V600E Mutation Positive Trial (Encorafenib Oral Capsule + Cetuximab)

        Not yet recruiting
        • Colorectal Cancer
        • BRAF V600E Mutation Positive
        • Encorafenib Oral Capsule + Cetuximab
        • (no location specified)
        Jan 30, 2023

        Melanoma Trial in Boston (Trametinib, Dabrafenib, INCB039110)

        Active, not recruiting
        • Melanoma
        • Boston, Massachusetts
          Massachusetts General Hospital
        Nov 1, 2021

        Colorectal Cancer Trial in Hangzhou (Surufatinib, Toripalimab, chemo)

        Recruiting
        • Colorectal Cancer
        • Hangzhou, Zhejiang, China
          First affiliated hospital, Zhejiang University
        Feb 26, 2022